This is a phase 3, placebo-controlled, double-blind, randomized study in participants with HeFH and elevated LDL-C to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) injection(s) of inclisiran. The study will be multicenter and international trial.
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.